Fig. 6: D-Pantothenic acid decreases NEU1 protein expression levels to rescue the cardiac injury induced by sotorasib.
From: Sotorasib-impaired degradation of NEU1 contributes to cardiac injury by inhibiting AKT signaling
A NEU1 expression levels in CCC-HEH-2 cells treated with sotorasib 20 μM and/or FDA-approved drug 10 μM for 48 h. B CCC-HEH-2 cells were treated with potential 9 intervention strategies (Nimodipine, pramipexole, Benzoyl peroxide, Dexpanthenol, Azilsartan, Enalapril Maleate Capsules, Carprofen, Sulfadiazine) 10 μM and/or sotorasib 20 μM for 48 h. c-PARP and NEU1 protein expression levels were examined in cells (n = 3). CCC-HEH-2 cells and/or H9c2 cells were treated with D-PAC (10 μM) or dexpanthenol (10 μM) in combination with sotorasib 20 μM or 60 μM for 48 h. C, D c-PARP and NEU1 protein expression levels were examined in cells (n = 3). E CCC-HEH-2 cells were treated with D-PAC (10 μM) or dexpanthenol (10 μM) in combination with sotorasib 20 μM for 48 h. MMP changes in CCC-HEH-2 cells (n = 3). CCC-HEH-2 cells cells were treated with D-PAC (10 μM) in combination with sotorasib 20 μM for 48 h. F ROS levels in CCCHEH-2 cells (n = 3). G AKT1 and p-AKT Ser473 protein expression levels were examined in cells (n = 3). H CCC-HEH-2 NEU1mRNA level (n = 3). I CHX (10 μg/mL), sotorasib (20 μM), and/or D-PAC treated 0, 2, 4, 8 h. NEU1 protein expression level (n = 3). Data expressed as mean ± SD, ***, p < 0.0001, **, p < 0.01, (vs. Vehicle), ###, p < 0.001, ##, p < 0.01 #, p < 0.05 (vs. sotorasib), ns, no significance.
